Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

HIGHLIGHTS

• who: Manuel Neuberger from the Methods , Study population and data collection Patients that were treated for either mHSPC or mCRPC between March , and September , at a certified prostate cancer centre of a tertiary university care centre (University Medical Centre Mannheim, Heidelberg University, Germany) were screened retrospectively. The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria were followed throughout this study. The inclusion criteria were (1) treatment with either docetaxel or cabazitaxel, (2) continuous treatment at the centre and (3) continuous androgen-deprivation therapy. Patients were excluded if taxanebased treatment was used as rechallenge. Previous androgen deprivation . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.